The Queen Elizabeth Hospital in Birmingham has announced that a 'groundbreaking' drug capable of delaying the onset of type 1 diabetes has been approved for use on the NHS. This development follows the ELSA (Early Surveillance for Autoimmune diabetes) screening study, the largest of its kind in the UK, which screened thousands of young people for antibodies indicating future type 1 diabetes risk.
Landmark study leads to NHS approval
Led by Professor Parth Narendran, the ELSA study screened children aged 2-15 and young adults aged 16-17 across Birmingham for markers of type 1 diabetes. The study's success has led to the approval of teplizumab, a drug that can delay the clinical onset of the condition. According to the hospital, this is the largest type 1 diabetes screening programme for individuals aged 2-17 in the UK.
In a Facebook post, Queen Elizabeth Hospital stated: 'In a UK first, 14-year-old Sam from Kings Norton received teplizumab at Birmingham Children’s Hospital early last year, gaining early access to the drug through the ELSA study.'
Voluntary screening and its purpose
The ELSA study is entirely voluntary, and the programme's website emphasizes that 'if you choose not to take part in the screening programme, this will not affect routine care in any way.' The site further explains: 'Type 1 diabetes is a lifelong and serious condition. Around the world, research studies are screening children and young adults for type 1 diabetes, so that we can find children and young adults at risk of the condition before they become unwell. This gives us the opportunity to test new treatments that could delay the start of type 1 diabetes.'
Impact on patients and future care
The approval of teplizumab marks a significant milestone in diabetes care, offering the potential to delay disease onset and reduce the burden of lifelong management. The ELSA study's findings underscore the importance of early detection and intervention, with the drug now available through the NHS for eligible individuals identified through screening.
